<!doctype html><html lang=zh-tw><head><meta charset=utf-8><meta name=description content="KFSYSCC Hematology Journal Reading How I treat
refractory CRS and ICANS
after CAR T-cell therapy ÊûóÂçîÈúÜ, Fellow 1  What are we going to discuss today?"><meta property="og:title" content><meta property="og:description" content><meta property="og:type" content="website"><meta property="og:url" content><meta property="og:image" content="https://og-mlkgi530p-htlin222.vercel.app/api/blog?templateTitle=How I treat refractory CRS and ICANS after CAR T-cell therapy"><title>How I treat refractory CRS and ICANS after CAR T-cell therapy</title><meta name=viewport content="width=device-width,initial-scale=1"><link rel=alternate type=application/rss+xml href=https://www.physician.tw//feed.xml title><link rel="shortcut icon" type=image/png href=https://www.physician.tw//icon.png><link href=https://www.physician.tw/styles.acd6336f837a791cf1889bb120dfb142.min.css rel=stylesheet><link href=https://www.physician.tw/styles/_light_syntax.86a48a52faebeaaf42158b72922b1c90.min.css rel=stylesheet id=theme-link><script src=https://www.physician.tw/js/darkmode.dfadb738e747a87e78c7144d7267f1bc.min.js></script>
<script src=https://www.physician.tw/js/util.6f22941e242efae60fd84e7c32e874fa.min.js></script>
<link rel=preload href=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/katex.min.css as=style onload='this.onload=null,this.rel="stylesheet"' integrity=sha384-R4558gYOUz8mP9YWpZJjofhk+zx0AS11p36HnD2ZKj/6JR5z27gSSULCNHIRReVs crossorigin=anonymous><script defer src=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/katex.min.js integrity=sha384-z1fJDqw8ZApjGO3/unPWUPsIymfsJmyrDVWC8Tv/a1HeOtGmkwNd/7xUS0Xcnvsx crossorigin=anonymous></script>
<script defer src=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/contrib/auto-render.min.js integrity=sha384-+XBljXPPiv+OzfbB3cVmLHf4hdUFHlWNZN5spNQ7rmHTXpd7WvJum6fIACpNNfIR crossorigin=anonymous></script>
<script defer src=https://cdn.jsdelivr.net/npm/katex@0.16.2/dist/contrib/copy-tex.min.js integrity=sha384-ww/583aHhxWkz5DEVn6OKtNiIaLi2iBRNZXfJRiY1Ai7tnJ9UXpEsyvOITVpTl4A crossorigin=anonymous></script>
<script async src=https://unpkg.com/@floating-ui/core@0.7.3></script>
<script async src=https://unpkg.com/@floating-ui/dom@0.5.4></script>
<script async src=https://www.physician.tw/js/popover.f03552ccb84d99ca615d1cfb9abde59e.min.js></script>
<script defer src=https://www.physician.tw/js/code-title.ce4a43f09239a9efb48fee342e8ef2df.min.js></script>
<script defer src=https://www.physician.tw/js/clipboard.2913da76d3cb21c5deaa4bae7da38c9f.min.js></script>
<script defer src=https://www.physician.tw/js/callouts.7723cac461d613d118ee8bb8216b9838.min.js></script>
<script>const SEARCH_ENABLED=!1,LATEX_ENABLED=!0,PRODUCTION=!0,BASE_URL="https://www.physician.tw/",fetchData=Promise.all([fetch("https://www.physician.tw/indices/linkIndex.aa8c081727de296f4eab0c29bb65f75f.min.json").then(e=>e.json()).then(e=>({index:e.index,links:e.links})),fetch("https://www.physician.tw/indices/contentIndex.4eb2d4533233a3401afa81e9da7edcfe.min.json").then(e=>e.json())]).then(([{index:e,links:t},n])=>({index:e,links:t,content:n})),render=()=>{const e=new URL(BASE_URL),t=e.pathname,n=window.location.pathname,s=t==n;addCopyButtons(),addTitleToCodeBlocks(),addCollapsibleCallouts(),initPopover("https://www.physician.tw",!0);const o=document.getElementById("footer");if(o){const e=document.getElementById("graph-container");if(!e)return requestAnimationFrame(render);e.textContent="";const t=s&&!1;drawGraph("https://www.physician.tw",t,[{"/moc":"#4388cc"}],t?{centerForce:1,depth:-1,enableDrag:!0,enableLegend:!1,enableZoom:!0,fontSize:.5,linkDistance:1,opacityScale:3,repelForce:1,scale:1.4}:{centerForce:1,depth:1,enableDrag:!0,enableLegend:!1,enableZoom:!0,fontSize:.6,linkDistance:1,opacityScale:3,repelForce:2,scale:1.2})}},init=(e=document)=>{addCopyButtons(),addTitleToCodeBlocks(),renderMathInElement(e.body,{delimiters:[{left:"$$",right:"$$",display:!0},{left:"$",right:"$",display:!1}],macros:{'‚Äô':"'"},throwOnError:!1})}</script><script type=module>
    import { attachSPARouting } from "https:\/\/www.physician.tw\/js\/router.9d4974281069e9ebb189f642ae1e3ca2.min.js"
    attachSPARouting(init, render)
  </script></head><body><div id=search-container><div id=search-space><input autocomplete=off id=search-bar name=search type=text aria-label=ÊêúÂ∞ã placeholder="Ë´ãËº∏ÂÖ•ÂÉèÊòØÔºöhypertension ‰πãÈ°ûÁöÑ‰æÜÁúãÊ≤íÊúâÊ≤í‰ªÄÈ∫ºÊúâË∂£ÁöÑüé≥"><div id=results-container></div></div></div><script src=https://cdn.jsdelivr.net/npm/flexsearch@0.7.21/dist/flexsearch.bundle.js integrity="sha256-i3A0NZGkhsKjVMzFxv3ksk0DZh3aXqu0l49Bbh0MdjE=" crossorigin=anonymous defer></script>
<script defer src=https://www.physician.tw/js/full-text-search.e6e2e0c213187ca0c703d6e2c7a77fcd.min.js></script><div class=singlePage><header><h1 id=page-title><a href=https://www.physician.tw/>Ëú•Ëú¥Ëä±Âúíü¶éüå±ü™¥üå≤</a></h1><div class=spacer></div><div id=search-icon><p>ÊêúÂ∞ã</p><svg tabindex="0" aria-labelledby="title desc" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 19.9 19.7"><title id="title">ÊêúÂ∞ãÂúñÁ§∫</title><desc id="desc">ÊâìÈñãÊêúÂ∞ãÂúñÊ®ô</desc><g class="search-path" fill="none"><path stroke-linecap="square" d="M18.5 18.3l-5.4-5.4"/><circle cx="8" cy="8" r="7"/></g></svg></div><div class=darkmode><input class=toggle id=darkmode-toggle type=checkbox tabindex=-1>
<label id=toggle-label-light for=darkmode-toggle tabindex=-1><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" id="dayIcon" viewBox="0 0 35 35" style="enable-background:new 0 0 35 35"><title>Êòé‰∫ÆÊ®°Âºè</title><path d="M6 17.5C6 16.672 5.328 16 4.5 16h-3C.672 16 0 16.672.0 17.5S.672 19 1.5 19h3C5.328 19 6 18.328 6 17.5zM7.5 26c-.414.0-.789.168-1.061.439l-2 2C4.168 28.711 4 29.086 4 29.5 4 30.328 4.671 31 5.5 31c.414.0.789-.168 1.06-.44l2-2C8.832 28.289 9 27.914 9 27.5 9 26.672 8.329 26 7.5 26zm10-20C18.329 6 19 5.328 19 4.5v-3C19 .672 18.329.0 17.5.0S16 .672 16 1.5v3C16 5.328 16.671 6 17.5 6zm10 3c.414.0.789-.168 1.06-.439l2-2C30.832 6.289 31 5.914 31 5.5 31 4.672 30.329 4 29.5 4c-.414.0-.789.168-1.061.44l-2 2C26.168 6.711 26 7.086 26 7.5 26 8.328 26.671 9 27.5 9zM6.439 8.561C6.711 8.832 7.086 9 7.5 9 8.328 9 9 8.328 9 7.5c0-.414-.168-.789-.439-1.061l-2-2C6.289 4.168 5.914 4 5.5 4 4.672 4 4 4.672 4 5.5c0 .414.168.789.439 1.06l2 2.001zM33.5 16h-3c-.828.0-1.5.672-1.5 1.5s.672 1.5 1.5 1.5h3c.828.0 1.5-.672 1.5-1.5S34.328 16 33.5 16zM28.561 26.439C28.289 26.168 27.914 26 27.5 26c-.828.0-1.5.672-1.5 1.5.0.414.168.789.439 1.06l2 2C28.711 30.832 29.086 31 29.5 31c.828.0 1.5-.672 1.5-1.5.0-.414-.168-.789-.439-1.061l-2-2zM17.5 29c-.829.0-1.5.672-1.5 1.5v3c0 .828.671 1.5 1.5 1.5s1.5-.672 1.5-1.5v-3C19 29.672 18.329 29 17.5 29zm0-22C11.71 7 7 11.71 7 17.5S11.71 28 17.5 28 28 23.29 28 17.5 23.29 7 17.5 7zm0 18c-4.136.0-7.5-3.364-7.5-7.5s3.364-7.5 7.5-7.5 7.5 3.364 7.5 7.5S21.636 25 17.5 25z"/></svg></label><label id=toggle-label-dark for=darkmode-toggle tabindex=-1><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" id="nightIcon" viewBox="0 0 100 100" style="enable-background='new 0 0 100 100'"><title>ÈªëÊöóÊ®°Âºè</title><path d="M96.76 66.458c-.853-.852-2.15-1.064-3.23-.534-6.063 2.991-12.858 4.571-19.655 4.571C62.022 70.495 50.88 65.88 42.5 57.5 29.043 44.043 25.658 23.536 34.076 6.47c.532-1.08.318-2.379-.534-3.23-.851-.852-2.15-1.064-3.23-.534-4.918 2.427-9.375 5.619-13.246 9.491-9.447 9.447-14.65 22.008-14.65 35.369.0 13.36 5.203 25.921 14.65 35.368s22.008 14.65 35.368 14.65c13.361.0 25.921-5.203 35.369-14.65 3.872-3.871 7.064-8.328 9.491-13.246C97.826 68.608 97.611 67.309 96.76 66.458z"/></svg></label></div></header><article><h1>How I treat refractory CRS and ICANS after CAR T-cell therapy</h1><p class=meta>ÊúÄÂæåÊõ¥Êñ∞Êñº
Sep 25, 2023
<a href=https://github.com/htlin222/garden/tree/hugo/content/slides/How%20I%20treat%20refractory%20CRS%20and%20ICANS%20after%20CAR%20T-cell%20therapy/backup_2023-10-02-02-21.md rel=noopener>ü™ö Á∑®ËºØÂéüÂßãÊñá‰ª∂</a></p><ul class=tags></ul><aside class=mainTOC><details><summary>üìíÁõÆÈåÑ</summary><nav id=TableOfContents><ol><li><ol><li></li></ol></li></ol><ol><li><a href=#ÊûóÂçîÈúÜ-fellow-1>ÊûóÂçîÈúÜ, Fellow 1</a></li><li><a href=#what-are-we-going-to-discuss-today>What are we going to discuss today?</a></li><li><a href=#introduction>Introduction</a></li><li><a href=#tocilizumab-and-corticosteroids-for-crs-and-icans>Tocilizumab and Corticosteroids for CRS and ICANS</a></li><li><a href=#astct-consensus-grading-for-crs>ASTCT Consensus Grading for CRS</a></li><li><a href=#grading-for-icans-part-i>Grading for ICANS: part I</a></li><li><a href=#grading-for-icans-part-ii>Grading for ICANS: part II</a></li><li><a href=#workup-or-evaluation-and-supportive-care-recommendations-all-grades>Workup or evaluation and supportive care recommendations (all grades)</a></li></ol><ol><li><a href=#case-1-refractory-crs-in-a-dlbcl-patient>Case 1: Refractory CRS in a DLBCL Patient</a></li><li><a href=#case-1-management-of-refractory-crs-in-a-dlbcl-patient>Case 1: Management of Refractory CRS in a DLBCL Patient</a></li><li><a href=#car-hematotox>CAR-HEMATOTOX</a><ol><li><a href=#a-model-for-car-t-cellrelated-hematologic-toxicity-in-relapsedrefractory-large-b-cell-lymphoma>a model for CAR T-cell‚Äìrelated hematologic toxicity in relapsed/refractory large B-cell lymphoma</a></li></ol></li><li><a href=#anakinra>Anakinra</a></li><li><a href=#differential-diagnosis-for-early-clinical-deterioration-after-car-t-cell-therapy>Differential Diagnosis for Early Clinical Deterioration after CAR T-cell Therapy</a></li><li><a href=#management-of-refractory-crs>Management of Refractory CRS</a></li><li><a href=#high-risk-of-developing-severe-crsicans-including-patients-with>High risk of developing severe CRS/ICANS, including patients with</a></li><li><a href=#case-2-cd19-car-t-cell-therapy-for-refractory-follicular-lymphoma-transformed-to-dlbcl>Case 2: CD19 CAR T-cell Therapy for Refractory Follicular Lymphoma Transformed to DLBCL</a></li><li><a href=#early-intervention-and-corticosteroid-use-in-car-t-cell-therapy>Early Intervention and Corticosteroid Use in CAR T-cell Therapy</a><ol><li><a href=#protocol-specified-ae-management-in-cohorts-1--2-and-cohort-4-of-zuma-1>Protocol-specified AE management in cohorts 1 + 2 and cohort 4 of ZUMA-1</a></li></ol></li><li><a href=#early-intervention-for-patients-at-high-risk-of-toxicity>Early Intervention for Patients at High Risk of Toxicity</a><ol><li></li></ol></li><li><a href=#management-of-grade-3-icans-in-a-patient-receiving-car-t-cell-therapy>Management of Grade 3 ICANS in a Patient Receiving CAR T-cell Therapy</a><ol><li><a href=#neurotoxicity-ntx-and-association-with-crs-after-conditioning-chemotherapy-and-1928z-car-t-cell-infusion>Neurotoxicity (NTX) and association with CRS after conditioning chemotherapy and 19‚Äì28z CAR T cell infusion</a></li></ol></li><li><a href=#use-of-corticosteroids-in-management-of-crs-and-icans>Use of Corticosteroids in Management of CRS and ICANS</a></li><li><a href=#case-3-use-of-cd19-car-t-cell-therapy-in--down-syndrome-and-rb-all>Case 3: Use of CD19 CAR T-cell Therapy in Down Syndrome and rB-ALL</a></li><li><a href=#management-of-adrenal-insufficiency-and-crs-mitigation-in-cd19-car-t-cell-therapy>Management of Adrenal Insufficiency and CRS Mitigation in CD19 CAR T-cell Therapy</a></li><li><a href=#development-and-management-of-hlh-like-complications-after-cd19-car-t-cell-therapy>Development and Management of HLH-Like Complications after CD19 CAR T-cell Therapy</a></li><li><a href=#hlh-like-toxicities-as-a-potential-complication-of-car-t-cell-therapy>HLH-Like Toxicities as a Potential Complication of CAR T-cell Therapy</a></li><li><a href=#management-of-hlh-like-toxicities-in-cd19-car-t-cell-therapy>Management of HLH-Like Toxicities in CD19 CAR T-cell Therapy</a></li></ol><ol><li><a href=#key-points>Key Points</a><ol><li></li><li><a href=#disease-type-and-biology>Disease type and biology</a></li><li><a href=#disease-burden>Disease burden</a></li><li><a href=#car-t-cell-construct>CAR T-cell construct</a></li></ol></li><li><a href=#pharmacologic-interventions-for-severe-andor-refractory-toxicities>Pharmacologic interventions for severe and/or refractory toxicities</a></li><li><a href=#anti-cytokine-directed>Anti-Cytokine Directed</a><ol><li><a href=#anakinra-1>Anakinra</a></li><li><a href=#siltuximab>Siltuximab</a></li><li><a href=#emapalumab>Emapalumab</a></li></ol></li><li><a href=#t-cell-targeted>T-Cell Targeted</a><ol><li><a href=#antithymocyte-globulin-atg>Antithymocyte globulin (ATG)</a></li><li><a href=#alemtuzumab-anti-cd52>Alemtuzumab (anti-CD52)</a></li><li><a href=#cyclophosphamide>Cyclophosphamide</a></li></ol></li><li><a href=#tkis>TKIs</a><ol><li><a href=#dasatinib-tki-bcr-abl>Dasatinib: TKI (BCR-ABL)</a></li><li><a href=#ibrutinib>Ibrutinib</a></li><li><a href=#ruxolitinib-or-alternative-jak1-inhibitors>Ruxolitinib or alternative JAK1 inhibitors</a></li></ol></li><li><a href=#car-t-cell-construct-based-safety-switches-in-cd19-car-t-cell-therapy>CAR T-Cell Construct-Based Safety Switches in CD19 CAR T-cell Therapy</a><ol><li><a href=#anti-car-t-cell-directed-strategies>Anti-CAR T-cell-directed strategies</a></li></ol></li><li><a href=#supportive-care-measures-for-management-of-severe-or-refractory-toxicities-in-cd19-car-t-cell-therapy>Supportive Care Measures for Management of Severe or Refractory Toxicities in CD19 CAR T-cell Therapy</a></li><li><a href=#supportive-care-measures-for-patients-with-severe-or-refractory-crs-or-icans-in-cd19-car-t-cell-therapy>Supportive Care Measures for Patients with Severe or Refractory CRS or ICANS in CD19 CAR T-cell Therapy</a><ol><li><a href=#neurology>Neurology</a></li><li><a href=#immunehematologic>Immune/Hematologic</a></li><li><a href=#infectious-disease>Infectious Disease</a></li><li><a href=#rehabilitation>Rehabilitation</a></li><li><a href=#cognitivepsychosocial>Cognitive/Psychosocial</a></li><li><a href=#medical>Medical</a></li><li><a href=#rehabilitation-and-cognitive-and-psychosocial-considerations>Rehabilitation and cognitive and psychosocial considerations</a></li></ol></li><li><a href=#conclusions>Conclusions</a></li><li><a href=#take-home-messages>Take Home Messages</a></li></ol></nav></details></aside><script src=https://cdn.jsdelivr.net/npm/markmap-autoloader@0.15.2></script>
<a href=#kfsyscc-hematology-journal-reading><h4 id=kfsyscc-hematology-journal-reading><span class=hanchor arialabel=Anchor># </span>KFSYSCC Hematology Journal Reading</h4></a><a href=#--fit--how-i-treatbrrefractory-brcrs-and-icansbrafter-car-t-cell-therapy><h1 id=--fit--how-i-treatbrrefractory-brcrs-and-icansbrafter-car-t-cell-therapy><span class=hanchor arialabel=Anchor># </span>How I treat<br><strong>refractory<br>CRS and ICANS</strong><br>after CAR T-cell therapy</h1></a><a href=#ÊûóÂçîÈúÜ-fellow-1><h2 id=ÊûóÂçîÈúÜ-fellow-1><span class=hanchor arialabel=Anchor># </span>ÊûóÂçîÈúÜ, Fellow 1</h2></a><hr><a href=#what-are-we-going-to-discuss-today><h2 id=what-are-we-going-to-discuss-today><span class=hanchor arialabel=Anchor># </span>What are we going to discuss today?</h2></a><p>:::half</p><ul><li>Diagnostic criteria for<ul><li><strong>cytokine release syndrome</strong> (CRS)</li><li><strong>immune effector cell‚Äìassociated neurotoxicity syndrome</strong> (ICANS)</li></ul></li><li><strong>Tocilizumab</strong> and <strong>corticosteroids</strong> are commonly used to treat CRS and ICANS.</li><li><strong>Preemptive</strong> interventions improve safety of CAR T-cell Tx.</li></ul><p>:::split</p><ul><li><strong>Anakinra</strong> is emerging as option.</li><li>Risk factors for severe toxicities</li><li>Mitigation strategies and supportive care measures can improve outcomes in patients with refractory toxicities.</li></ul><p>:::</p><hr><a href=#introduction><h2 id=introduction><span class=hanchor arialabel=Anchor># </span>Introduction</h2></a><ul><li>CAR T-cell therapy is potent, but toxicity mitigation is necessary</li><li>definition and grading systems for CRS and <strong>immune effector cell‚Äìassociated neurotoxicity syndrome</strong> (ICANS) have been developed.</li><li>Severe toxicities, including refractoriness to standard management with tocilizumab and steroids, still occur.</li></ul><p>!!! warning
<em>Despite the current stard of treatment, why there&rsquo;s still severe toxicities happend?</em></p><hr><a href=#tocilizumab-and-corticosteroids-for-crs-and-icans><h2 id=tocilizumab-and-corticosteroids-for-crs-and-icans><span class=hanchor arialabel=Anchor># </span>Tocilizumab and Corticosteroids for CRS and ICANS</h2></a><ul><li>Tocilizumab and corticosteroids were initially used for severe CRS and/or ICANS.</li><li>Now, these therapies are increasingly used at <strong>earlier stages</strong> to reduce the incidence of severe toxicity.<ul><li><strong>Pre-emptive</strong> tocilizumab and/or steroids with lower grade toxicity can prevent more severe manifestations.</li><li><strong>Prophylactic treatment</strong> before any toxicity is observed is also being explored.</li></ul></li><li>Refractory CRS and/or ICANS are defined as <strong>persistent or progressive disease despite optimal use of tocilizumab and/or steroids.</strong></li><li>Available strategies have shifted towards <strong>prevention</strong> of ‚â•grade <strong>3</strong> CRS and ICANS.</li></ul><hr><a href=#astct-consensus-grading-for-crs><h2 id=astct-consensus-grading-for-crs><span class=hanchor arialabel=Anchor># </span>ASTCT Consensus Grading for CRS</h2></a><table><thead><tr><th>Clinical Parameter</th><th>Grade 1</th><th>Grade 2</th><th>Grade 3</th><th>Grade 4</th></tr></thead><tbody><tr><td>Fever</td><td>‚â•38 C</td><td>‚â•38 C</td><td>‚â•38 C</td><td>‚â•38 C</td></tr><tr><td>Hypotension</td><td>None</td><td>No vasopressors</td><td>Vasopressor ¬± vasopressin</td><td>Requires multiple vasopressors<br>(not vasopressin)</td></tr><tr><td>Hypoxia</td><td>None</td><td>Low-flow nasal cannula or blow-by</td><td>High-flow nasal cannula, face mask,<br>non-rebreather, Venturi mask</td><td>CPAP, BiPAP, mechanical ventilation</td></tr></tbody></table><p>!!! attention
In grades 2 to 4, inclusion is fever plus hypotension and/or hypoxia.</p><blockquote><p>Lee D, Santomasso B, Locke F, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25:625-638.</p></blockquote><hr><a href=#grading-for-icans-part-i><h2 id=grading-for-icans-part-i><span class=hanchor arialabel=Anchor># </span>Grading for ICANS: part I</h2></a><p><img src=https://i.imgur.com/yWs8FM3.png width=auto alt="Figure: height:550px"></p><hr><a href=#grading-for-icans-part-ii><h2 id=grading-for-icans-part-ii><span class=hanchor arialabel=Anchor># </span>Grading for ICANS: part II</h2></a><p><img src=https://i.imgur.com/TURFUWh.png width=auto alt="Figure: width:1150px"></p><p><img src=https://i.imgur.com/4Ez7otw.png width=auto alt="Figure: width:1150px"></p><blockquote><p>Lee, Daniel W., et al. &ldquo;ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells.&rdquo; Biology of blood and marrow transplantation 25.4 (2019): 625-638.</p></blockquote><hr><a href=#workup-or-evaluation-and-supportive-care-recommendations-all-grades><h2 id=workup-or-evaluation-and-supportive-care-recommendations-all-grades><span class=hanchor arialabel=Anchor># </span>Workup or evaluation and supportive care recommendations (all grades)</h2></a><ul><li>CBC, CMP, Mg, Phos, CRP, LDH, uric acid, fibrinogen, PT/PTT, and ferritin</li><li>blood and urine cultures, CXR</li><li>If <strong>neutropenic</strong>, follow institutional neutropenic fever guidelines</li><li>If grade 2 or higher CRS (eg, shock or hypoxia)<ul><li>should be monitored with continuous cardiac telemetry and pulse oximetry.</li></ul></li><li>severe CRS, consider performing an echocardiogram to assess cardiac function.</li><li>Perform cardiac monitoring in patients who experience at least G2 CRS, clinically significant arrhythmia, and additionally as clinically indicated</li><li>Consider screening for <strong>CMV</strong> and <strong>EBV</strong></li><li>Consider chest or abdominal CT imaging, brain MRI, and/or lumbar puncture.</li></ul><blockquote><p>Santomasso BD, Nastoupil LJ, Adkins S, et al. Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline. J Clin Oncol. 2021;39(35):3978-3992. doi:10.1200/JCO.21.01992</p></blockquote><hr><a href=#cases><h1 id=cases><span class=hanchor arialabel=Anchor># </span>Cases</h1></a><hr><a href=#case-1-refractory-crs-in-a-dlbcl-patient><h2 id=case-1-refractory-crs-in-a-dlbcl-patient><span class=hanchor arialabel=Anchor># </span>Case 1: Refractory CRS in a DLBCL Patient</h2></a><ul><li>A 59-year-old male</li><li><code>DLBCL</code> received CD19 CAR T-cell therapy after 3 prior lines of therapy.</li><li>On day 0, he developed grade 1 CRS and progressed to grade 2 CRS with hypoxia by day 3.</li><li><code>Tocilizumab at 8 mg/kg</code> was administered, but he required a second dose and <code>dexamethasone, 10 mg IV every 6 hours</code>, because of persistent fevers and worsening hypoxia.</li><li>By day 4, <strong>ferritin x3 within 24 hours to 23,000 ng/mL</strong>, ‚Üí ICU for high-flow oxygen and vasopressors.</li><li>DIC, thrombocytopenia, and AKI creatinine ‚â•3 mg/dL.</li><li>The corticosteroid dose was increased to <code>methylprednisolone 1 g IV daily</code>.</li></ul><hr><p>:::half</p><ul><li>Patients with <strong>high tumor burden and primary refractory disease</strong> are<ul><li>at high risk of both CRS and lymphoma relapse.</li></ul></li><li>CD19 CAR T-cell products incorporating 4-1BB (ie, tisagenlecleucel) have lower toxicity rates than those costimulated by CD28 (axi-cel), but severe CRS has been reported for all products.</li></ul><p>!!! info
tisa-cel lower toxicity than axi-cel</p><p>:::split</p><p><img src=https://i.imgur.com/yvF6ilP.png width=auto alt=height:250px></p><p><img src=https://i.imgur.com/Jo8zGwZ.png width=auto alt=height:250px></p><p>:::</p><blockquote><p>Dean EA, Mhaskar RS, Lu H, et al. High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma. Blood Advances. 2020;4(14):3268-3276. doi:10.1182/bloodadvances.2020001900</p></blockquote><hr><ul><li>With persistent grade 2 CRS despite repeat doses of tocilizumab and/or single dose corticosteroids, or progression to grade 3 CRS,<ul><li>dexamethasone is often escalated up to <strong>10 mg IV every 6 hours</strong>.</li><li><strong>methylprednisolone 1 g IV per day</strong> and/or initiation of alternative CRS-directed therapies.</li></ul></li><li>Once a patient has received 2 doses of tocilizumab<ul><li>repeat doses are generally not recommended.</li></ul></li><li>Consideration of both alternative etiologies and incorporation of additional therapies is imperative for refractory CRS.</li></ul><p>!!! Warning
Tocilizumab maximum two dose</p><hr><a href=#case-1-management-of-refractory-crs-in-a-dlbcl-patient><h2 id=case-1-management-of-refractory-crs-in-a-dlbcl-patient><span class=hanchor arialabel=Anchor># </span>Case 1: Management of Refractory CRS in a DLBCL Patient</h2></a><ul><li>Concurrent infections, including bacteremia and CMV viremia, were identified in the patient with refractory CRS.<ul><li>Antibiotics and CMV treatment were initiated.</li></ul></li><li>Early restaging via abdominal CT scan showed<ul><li>stabilization of the abdominal mass.</li></ul></li><li><strong>Anakinra 100 mg IV every 6 hours</strong> was started on the afternoon of day 4 for refractory CRS.</li><li>The patient&rsquo;s condition subsequently improved, and anakinra and corticosteroid doses were tapered over 1 week.</li><li>He experienced a maximum ICANS of grade 1.</li><li>His day 30 positron emission tomography/CT scan showed a complete metabolic remission</li></ul><hr><a href=#car-hematotox><h2 id=car-hematotox><span class=hanchor arialabel=Anchor># </span>CAR-HEMATOTOX</h2></a><a href=#a-model-for-car-t-cellrelated-hematologic-toxicity-in-relapsedrefractory-large-b-cell-lymphoma><h3 id=a-model-for-car-t-cellrelated-hematologic-toxicity-in-relapsedrefractory-large-b-cell-lymphoma><span class=hanchor arialabel=Anchor># </span>a model for CAR T-cell‚Äìrelated hematologic toxicity in relapsed/refractory large B-cell lymphoma</h3></a><p><img src=https://i.imgur.com/qOzleBL.png width=auto alt="Figure: width:1150px"></p><blockquote><p>Rejeski, K., Perez, A., Iacoboni, G., Penack, O., B√ºcklein, V., Jentzsch, L., &mldr; & Subklewe, M. (2022). The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL. Journal for ImmunoTherapy of Cancer, 10(5).</p></blockquote><hr><a href=#anakinra><h2 id=anakinra><span class=hanchor arialabel=Anchor># </span>Anakinra</h2></a><ul><li>Disease-modifying Antirheumatic Drugs</li><li>Recombinant human <code>interleukin-1 (IL-1)</code> receptor antagonist</li><li>Administer <strong>sub-Q, 100mg</strong></li><li>Uses: Rheumatoid Arthritis, Cryopyrin-associated Periodic Syndromes, Deficiency of Interleukin-1 Receptor Antagonist</li><li>Warnings:<ul><li>Opportunistic infections (fungal, mycobacterial, bacterial)</li><li>Concomitant use of TNF blocking agents (e.g., adalimumab, etanercept, infliximab) not recommended.</li><li>Neutropenia</li></ul></li></ul><hr><a href=#differential-diagnosis-for-early-clinical-deterioration-after-car-t-cell-therapy><h2 id=differential-diagnosis-for-early-clinical-deterioration-after-car-t-cell-therapy><span class=hanchor arialabel=Anchor># </span>Differential Diagnosis for Early Clinical Deterioration after CAR T-cell Therapy</h2></a><ul><li>Top differential diagnoses include:<ul><li><strong>refractory CRS</strong>, <strong>infection</strong>, and <strong>cancer progression</strong>.</li></ul></li><li>Infectious workup includes standard cultures performed at first fever and every 24 to 48 hours while the patient is persistently febrile.<ul><li><strong>CMV/adenoviremia</strong> and other viremias,</li><li>nasopharyngeal viral testing for respiratory infections</li></ul></li><li>The patient had no evidence of gastrointestinal perforation or ischemia, which can occur among patients with abdominal lymphoma.</li></ul><hr><a href=#management-of-refractory-crs><h2 id=management-of-refractory-crs><span class=hanchor arialabel=Anchor># </span>Management of Refractory CRS</h2></a><ul><li>For CRS refractory to high doses of corticosteroids:<ul><li><strong>anakinra</strong> often considered.</li></ul></li><li>Once a clinical response is achieved, anakinra and corticosteroids:<ul><li>tapered as indicated, prolonged use at high doses is not indicated.</li></ul></li><li>Extra vigilance and enhanced antimicrobial prophylaxis is warranted,</li><li><strong>Cytopenias</strong> are a complication of, and can further complicate, refractory CRS</li></ul><p>!!! Warning
prolonged use at high doses is not indicated</p><hr><a href=#high-risk-of-developing-severe-crsicans-including-patients-with><h2 id=high-risk-of-developing-severe-crsicans-including-patients-with><span class=hanchor arialabel=Anchor># </span>High risk of developing severe CRS/ICANS, including patients with</h2></a><ul><li>older patients</li><li>medically frail</li><li>bulky disease</li><li>high tumor burden</li></ul><hr><a href=#case-2-cd19-car-t-cell-therapy-for-refractory-follicular-lymphoma-transformed-to-dlbcl><h2 id=case-2-cd19-car-t-cell-therapy-for-refractory-follicular-lymphoma-transformed-to-dlbcl><span class=hanchor arialabel=Anchor># </span>Case 2: CD19 CAR T-cell Therapy for Refractory Follicular Lymphoma Transformed to DLBCL</h2></a><ul><li>A 71-year-old woman</li><li><strong>follicular lymphoma</strong> transformed to DLBCL was referred for receipt of CD19 CAR T cells for treatment of progressive nodal and extranodal disease refractory to 3 prior lines of therapy.</li><li>She was not given any bridging therapy before axicabtagene ciloleucel.</li><li>On day 2, she developed grade 1 CRS, with persistent fever until day 5, when she was given dexamethasone 10 mg IV once.</li><li>On day 6, she presented with grade 2 CRS and grade 1 ICANS characterized by fever, hypoxia, and dysphasia.</li><li>She received <strong>tocilizumab 8 mg/kg</strong> and <strong>dexamethasone 10 mg IV</strong> once for the ICANS.</li></ul><hr><a href=#early-intervention-and-corticosteroid-use-in-car-t-cell-therapy><h2 id=early-intervention-and-corticosteroid-use-in-car-t-cell-therapy><span class=hanchor arialabel=Anchor># </span>Early Intervention and Corticosteroid Use in CAR T-cell Therapy</h2></a><ul><li>The comparison of cohorts 1 and 2 with cohort 4 found that the median overall corticosteroid exposure declined from 6886 mg to 939 mg with earlier use of corticosteroids.</li><li>Overall, the trend in clinical practice is toward intervening earlier at lower grades of CRS and ICANS.</li><li>Age alone is not a driving factor for toxicity severity, as shown by findings from studies such as Ram et al&rsquo;s comparison of geriatric and younger patients.</li></ul><p>!!! Info
<strong>Earlier intervention</strong> with corticosteroids may help to limit a more prolonged course of corticosteroids.</p><hr><a href=#protocol-specified-ae-management-in-cohorts-1--2-and-cohort-4-of-zuma-1><h3 id=protocol-specified-ae-management-in-cohorts-1--2-and-cohort-4-of-zuma-1><span class=hanchor arialabel=Anchor># </span>Protocol-specified AE management in cohorts 1 + 2 and cohort 4 of ZUMA-1</h3></a><a href=#a-comparison-of-ae-management-in-cohorts-1--2-and-cohort-4-of-zuma-1-yes-or-no-indicates-whether-tocilizumab-or-corticosteroid-was-or-was-not-administered-respectively><h4 id=a-comparison-of-ae-management-in-cohorts-1--2-and-cohort-4-of-zuma-1-yes-or-no-indicates-whether-tocilizumab-or-corticosteroid-was-or-was-not-administered-respectively><span class=hanchor arialabel=Anchor># </span>(A) Comparison of AE management in cohorts 1 + 2 and cohort 4 of ZUMA-1. ‚ÄòYes‚Äô or ‚ÄòNo‚Äô indicates whether tocilizumab or corticosteroid was or was not administered, respectively</h4></a><p><img src=https://i.imgur.com/isYtII7.png width=auto alt="Figure: width:1150px"></p><blockquote><p>Topp, Max S., et al. &ldquo;Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B‚Äêcell lymphoma.&rdquo; British Journal of Haematology 195.3 (2021): 388-398.</p></blockquote><hr><p>:::free</p><p><img src=https://i.imgur.com/TmsjUwj.png width=auto alt="Figure: height:550px"></p><p>:::split</p><p>(B) Tocilizumab and corticosteroid guidelines for AE management in cohort 4 of ZUMA-1.</p><p>:::</p><blockquote><p>Topp, Max S., et al. &ldquo;Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B‚Äêcell lymphoma.&rdquo; British Journal of Haematology 195.3 (2021): 388-398.</p></blockquote><hr><a href=#early-intervention-for-patients-at-high-risk-of-toxicity><h2 id=early-intervention-for-patients-at-high-risk-of-toxicity><span class=hanchor arialabel=Anchor># </span>Early Intervention for Patients at High Risk of Toxicity</h2></a><ul><li>In patients who may not tolerate prolonged low-grade CRS (such as elderly patients or those who are frail) or patients who are at high risk of subsequent progression to severe toxicities, early intervention with tocilizumab and/or corticosteroids during lower grade toxicities is recommended.</li><li>Although results of studies incorporating prophylactic corticosteroids are promising, additional studies are needed before systematically incorporating the prophylactic use of steroids for risk mitigation.</li></ul><p>!!! Info
elderly patients or those who are frail üëâ ppx corticosteroids</p><hr><a href=#back-to-case-3><h4 id=back-to-case-3><span class=hanchor arialabel=Anchor># </span>Back to Case 3</h4></a><a href=#management-of-grade-3-icans-in-a-patient-receiving-car-t-cell-therapy><h2 id=management-of-grade-3-icans-in-a-patient-receiving-car-t-cell-therapy><span class=hanchor arialabel=Anchor># </span>Management of Grade 3 ICANS in a Patient Receiving CAR T-cell Therapy</h2></a><ul><li>On day 8, the patient showed <strong>global aphasia</strong> and <strong>epileptiform activity</strong> upon an EEG, consistent with <strong>grade 3 ICANS</strong>,<ul><li>despite concurrent improvement in CRS to grade 1</li></ul></li><li>For treatment of ICANS, she received <strong>methylprednisolone 1 gm IV daily for 2 days</strong> followed by a dexamethasone taper to discontinuation over 2 weeks.</li><li>She also received <strong>anakinra 100 mg IV</strong> every 6 hours, which was tapered over a 10-day course.</li><li>Seizure prophylaxis with levetiracetam (500 mg daily) was increased to therapeutic doses and 2 additional antiepileptics, lacosamide and phenytoin, were initiated to control seizure activity based on neurology consultation.</li></ul><hr><a href=#neurotoxicity-ntx-and-association-with-crs-after-conditioning-chemotherapy-and-1928z-car-t-cell-infusion><h3 id=neurotoxicity-ntx-and-association-with-crs-after-conditioning-chemotherapy-and-1928z-car-t-cell-infusion><span class=hanchor arialabel=Anchor># </span>Neurotoxicity (NTX) and association with CRS after conditioning chemotherapy and 19‚Äì28z CAR T cell infusion</h3></a><p>:::half</p><p><img src=https://i.imgur.com/fHn202f.png width=auto alt="Figure: height:450px"></p><p>:::split</p><p><img src=https://i.imgur.com/IBRDddD.png width=auto alt="Figure: height:450px"></p><p>:::</p><blockquote><p>Santomasso, Bianca D., et al. &ldquo;Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia.&rdquo; Cancer discovery 8.8 (2018): 958-971.</p></blockquote><hr><ul><li>The patient was treated in the ICU for several days for more frequent monitoring of her neurological status.</li><li>Upon resolution of CRS and ICANS, she was noted to have CMV viremia, cytopenias, and severe deconditioning, which substantially prolonged her inpatient stay.</li><li>Her day 30 positron emission tomography/CT scan showed a complete metabolic remission, and she was ultimately discharged from the hospital on day 65 after CAR T-cell infusion.</li></ul><p><img src="https://emojik.vercel.app/s/%f0%9f%8c%b7_%f0%9f%8e%8a?size=256" width=auto alt="emojik RLQ height:100px"></p><hr><a href=#use-of-corticosteroids-in-management-of-crs-and-icans><h2 id=use-of-corticosteroids-in-management-of-crs-and-icans><span class=hanchor arialabel=Anchor># </span>Use of Corticosteroids in Management of CRS and ICANS</h2></a><ul><li>Corticosteroids are generally accepted for refractory CRS and as first-line therapy for ICANS.</li><li>Dexamethasone is frequently recommended for ICANS because it crosses the <strong>blood-brain barrier</strong>.</li><li>Package inserts for US FDA-approved CD19 CAR T-cell products recommend dexamethasone or methylprednisolone for the treatment of severe ICANS.</li><li>There are <em>conflicting data</em> on the impact that corticosteroid exposure has on CAR T-cell efficacy, with some studies noting no change in the efficacy, whereas others show decreased efficacy.</li></ul><hr><ul><li>The use of <strong>intrathecal corticosteroids</strong> has also been reported for use in severe or refractory ICANS, yet its use as a systemic steroid-sparing therapy warrants prospective study.</li><li>TODO: find out what is the intrathecal corticosteroid ????</li><li>The use of intrathecal therapy may be limited by concurrent thrombocytopenia and coagulopathy observed in patients with concurrent CRS.</li></ul><hr><a href=#case-3-use-of-cd19-car-t-cell-therapy-in--down-syndrome-and-rb-all><h2 id=case-3-use-of-cd19-car-t-cell-therapy-in--down-syndrome-and-rb-all><span class=hanchor arialabel=Anchor># </span>Case 3: Use of CD19 CAR T-cell Therapy in Down Syndrome and rB-ALL</h2></a><ul><li>A 15-year-old male with constitutional trisomy 21 and<ul><li>relapsed B-cell acute lymphoblastic leukemia (B-ALL)</li><li>presented with 30% bone marrow blasts with low-level circulating peripheral blasts.</li></ul></li><li>The patient received LD chemotherapy and CAR T-cell infusion for relapsed B-ALL with 30% marrow involvement after bridging chemotherapy.</li><li>He was on physiologic hydrocortisone for adrenal insufficiency.</li><li>He developed fever, representing grade 1 CRS, on day 5 and was initially responsive to supportive measures.</li><li>However, he developed more persistent fevers, hypotension, rising creatinine, and decreasing urine output (grade 2 CRS) over 3 days.</li><li>He was given tocilizumab 8 mg/kg for persistent grade 2 CRS to prevent grade 3 CRS.</li></ul><hr><a href=#management-of-adrenal-insufficiency-and-crs-mitigation-in-cd19-car-t-cell-therapy><h2 id=management-of-adrenal-insufficiency-and-crs-mitigation-in-cd19-car-t-cell-therapy><span class=hanchor arialabel=Anchor># </span>Management of Adrenal Insufficiency and CRS Mitigation in CD19 CAR T-cell Therapy</h2></a><ul><li>For patients with established or suspected adrenal insufficiency, maintenance of physiologic dosing with escalation to stress-dosing during CRS should be considered to maintain hemodynamic stability and offset the need for higher doses of corticosteroids.</li><li>Consistent with preemptive strategies tested by Gardner et al, tocilizumab was given for persistent symptoms of mild CRS and before the development of life-threatening toxicities (eg, grade 3 CRS).</li><li>The approach of preventing more severe CRS/ICANS in children and young adults may be a unique consideration of younger patients in which baseline comorbidities may be less severe, and patients may be able to better tolerate grade 2 CRS/ICANS without more severe complications.</li><li>In patients with DS: monitor congenital cardiac complications.</li></ul><hr><a href=#development-and-management-of-hlh-like-complications-after-cd19-car-t-cell-therapy><h2 id=development-and-management-of-hlh-like-complications-after-cd19-car-t-cell-therapy><span class=hanchor arialabel=Anchor># </span>Development and Management of HLH-Like Complications after CD19 CAR T-cell Therapy</h2></a><ul><li>Approximately 10 days after tocilizumab, the patient developed a rapidly rising <strong>ferritin level</strong> (>100 000 Œºg/L) and hepatic transaminitis (>10 √ó upper limit of normal [ULN]), disproportional to C-reactive protein, which was decreasing.</li><li>The patient also developed severe <strong>hypofibrinogenemia</strong> (&lt;100 mg/dL)</li><li>Despite stable vital signs, laboratory parameters worsened, prompting the initiation of methylprednisolone (2 mg/kg per day) and anakinra (8 mg/kg per day) to treat <strong>HLH-like complications</strong>.</li><li>After a short course of steroids and 1 week of anakinra with tapering doses, laboratory values normalized.</li><li>The patient achieved a minimal residual disease-negative complete response.</li></ul><hr><a href=#hlh-like-toxicities-as-a-potential-complication-of-car-t-cell-therapy><h2 id=hlh-like-toxicities-as-a-potential-complication-of-car-t-cell-therapy><span class=hanchor arialabel=Anchor># </span>HLH-Like Toxicities as a Potential Complication of CAR T-cell Therapy</h2></a><ul><li>Recently termed as <strong>immune effector cell-associated HLH-like syndrome</strong> (IEC-HS) through an American Society for Transplantation and Cellular Therapy (ASTCT) effort, this hyperinflammatory syndrome manifests with cytopenia, hepatic dysfunction, hypofibrinogenemia, and hyperferritinemia.</li><li>Because both primary/familial and secondary forms of HLH are pathologically linked to T-cell activation and immune dysregulation, this complication can be particularly challenging to diagnose with underlying hematologic malignancies.</li><li>Initially described as part of severe CRS, more recent reports have described delayed manifestations of HLH-like toxicities even with low-grade CRS, particularly in patients receiving <strong>CD22</strong> CAR T cells.</li><li>In BCMA-targeting CAR T-cell therapies, in which severe CRS is less frequent, HLH-or macrophage activation syndrome-like toxicities are also becoming more apparent and are listed as potential toxicities on the FDA-approved package inserts.</li></ul><hr><a href=#management-of-hlh-like-toxicities-in-cd19-car-t-cell-therapy><h2 id=management-of-hlh-like-toxicities-in-cd19-car-t-cell-therapy><span class=hanchor arialabel=Anchor># </span>Management of HLH-Like Toxicities in CD19 CAR T-cell Therapy</h2></a><ul><li>In case 3, <strong>anakinra and corticosteroids</strong> were used as first-line strategies based on their established role in the treatment of primary or secondary HLH.</li><li>This approach has been recently endorsed by the ASTCT Committee on Cellular Therapy, although further study is needed.</li><li>Tocilizumab was not indicated in case 3, as the patient&rsquo;s clinical presentation and stable vital signs did not meet the standard criteria for CRS.</li><li>Multicenter efforts are ongoing to establish clear criteria to improve understanding of IEC-HS and formulate optimal treatment approaches, particularly for refractory cases.</li><li>Therapeutic strategies for refractory IEC-HS are under study and include ruxolitinib, emapalumab, and etoposide.</li></ul><hr><p><br><br><br></p><a href=#prevention-of-severe-andor-refractory-crsicans><h1 id=prevention-of-severe-andor-refractory-crsicans><span class=hanchor arialabel=Anchor># </span>Prevention of severe and/or refractory CRS/ICANS</h1></a><hr><a href=#key-points><h2 id=key-points><span class=hanchor arialabel=Anchor># </span>Key Points</h2></a><ul><li>Distinguishing toxicities that respond to first-line approaches from those requiring additional investigations or interventions is a critical consideration.</li><li>Early identification and preemptive interventions in high risk pt</li><li>Risk-mitigation preventive strategies for those at high risk of toxicity may improve outcomes.</li></ul><hr><a href=#approach-to-mitigate-severe-crsicans-and-progressive-toxicities-despite-the-optimal-use-of-first-line-therapies><h4 id=approach-to-mitigate-severe-crsicans-and-progressive-toxicities-despite-the-optimal-use-of-first-line-therapies><span class=hanchor arialabel=Anchor># </span>Approach to mitigate severe CRS/ICANS and progressive toxicities despite the optimal use of first-line therapies</h4></a><p><img src=https://i.imgur.com/uBnwbc5.png width=auto alt="Figure: height:550px"></p><hr><a href=#disease-type-and-biology><h3 id=disease-type-and-biology><span class=hanchor arialabel=Anchor># </span>Disease type and biology</h3></a><ul><li>Highly proliferative aggressive diseases, are at higher risk of severe CRS/ICANS than diseases,<ul><li>DLBCL and B-ALL, follicular lymphoma, or myeloma.</li></ul></li><li><strong>marginal zone lymphoma</strong> has a higher rate of CRS/ICANS than follicular lymphoma, and transformed marginal zone lymphoma may be at higher risk than transformed follicular lymphoma or de novo DLBCL.</li><li>severe and refractory CRS and ICANS may occur in any disease type,<ul><li>especially among heavily pretreated and refractory patients.</li></ul></li><li>Management recommendations for cases of severe and refractory CRS or ICANS are generalizable across disease types.</li></ul><hr><a href=#disease-burden><h3 id=disease-burden><span class=hanchor arialabel=Anchor># </span>Disease burden</h3></a><ul><li>higher inflammatory cytokine levels and CAR T-cell expansion.<ul><li>increased risk of relapse after CAR T-cell therapy, even though remission rates are often comparable.</li></ul></li><li>severe CRS are at a higher risk for CAR T-cell failure.</li><li>Debunking patients before CAR T-cell therapy can be tried, but patients receive CAR T-cell therapy because they are resistant to other treatments.</li><li>Debulking radiation, however, the optimal timing, dose, and field for bridging radiation therapy are unknown.</li></ul><p>!!! Warning
rapidly progressive disease, high tumor burdens, or poor performance status may be better candidates for therapies other than CAR T cells.</p><hr><a href=#car-t-cell-construct><h3 id=car-t-cell-construct><span class=hanchor arialabel=Anchor># </span>CAR T-cell construct</h3></a><ul><li><strong>CD28-costimulated</strong> CAR T-cell products demonstrate higher rates of CRS and ICANS compared to 4-1BB-costimulated products in DLBCL with CD19 CAR T cells.</li><li>ICANS may be more severe when <strong>targeting CD19</strong>, potentially because of the on-target, off-tumor targeting of CD19 on <strong>brain mural cells</strong>.</li><li>Unique movement-related toxicities have been observed when targeting BCMA, possibly because of off-tumor expression of these targets in and around the brain.</li><li>Even when the target and costimulatory domain are identical, kinetics of toxicity may differ between products, affecting clinical management.</li></ul><p>!!! info
When multiple CAR T-cell products are available for a given disease, consideration of a product with potentially lower toxicity</p><hr><a href=#pharmacologic-interventions-for-severe-andor-refractory-toxicities><h2 id=pharmacologic-interventions-for-severe-andor-refractory-toxicities><span class=hanchor arialabel=Anchor># </span>Pharmacologic interventions for severe and/or refractory toxicities</h2></a><ul><li>Evidence-based data on the use of pharmacologic interventions for treatment of severe and/or refractory toxicities in CD19 CAR T-cell therapy are generally lacking.</li><li>Limited data is available from single-institutional experiences or case reports, preclinical data, T-cell‚Äìdirected mechanisms of action, or adopted for use based on efficacy in alternative hyperinflammatory settings.</li><li>Risk of infection with additive use of immunosuppressive agents is a concern.</li><li>Consultation with infectious disease specialists is suggested to optimize infection surveillance strategies and use of prophylactic/preemptive antimicrobials.</li></ul><hr><a href=#anti-cytokine-directed><h2 id=anti-cytokine-directed><span class=hanchor arialabel=Anchor># </span>Anti-Cytokine Directed</h2></a><a href=#anakinra-1><h3 id=anakinra-1><span class=hanchor arialabel=Anchor># </span>Anakinra</h3></a><ul><li><strong>IL-1</strong> receptor antagonist.<ul><li>reduce signs/symptoms and slow the progression of damage in<ul><li>adults with moderately to severely active RA who have failed ‚â•1 DMARDs, or</li><li>neonatal-onset multisystem inflammatory disorder.</li></ul></li><li>Administered by IV or SC, with preference for IV administration in patients with edema in whom SC administration may not be as reliable.</li></ul></li></ul><a href=#siltuximab><h3 id=siltuximab><span class=hanchor arialabel=Anchor># </span>Siltuximab</h3></a><ul><li><strong>IL-6</strong> antagonist.<ul><li>for <strong>multicentric Castleman disease</strong> who are HIV- and HHV-8‚Äìnegative.</li><li>limited to <strong>2L</strong> or rCRS/ICANS after the use of multiple other agents.</li></ul></li></ul><hr><a href=#emapalumab><h3 id=emapalumab><span class=hanchor arialabel=Anchor># </span>Emapalumab</h3></a><ul><li><strong>IFN-Œ≥‚Äìblocking</strong> antibody.</li><li>Used for the treatment of adult and pediatric patients with primary HLH with refractory, recurrent, or progressive disease or intolerance to conventional HLH therapy.</li><li>Clinical experience is limited.</li></ul><hr><a href=#t-cell-targeted><h2 id=t-cell-targeted><span class=hanchor arialabel=Anchor># </span>T-Cell Targeted</h2></a><a href=#antithymocyte-globulin-atg><h3 id=antithymocyte-globulin-atg><span class=hanchor arialabel=Anchor># </span>Antithymocyte globulin (ATG)</h3></a><ul><li>Direct T-cell targeting.</li><li>Used for prophylaxis and treatment of acute rejection in patients receiving a kidney transplant, or use in conjunction with concomitant immunosuppression.</li><li>Potential use is based on clinical efficacy of targeting T cells.</li><li>Data on CRS/ICANS are limited.</li><li>Risk of infection/immunosuppression is high.</li></ul><hr><a href=#alemtuzumab-anti-cd52><h3 id=alemtuzumab-anti-cd52><span class=hanchor arialabel=Anchor># </span>Alemtuzumab (anti-CD52)</h3></a><ul><li>Depletion of T and B cells by binding to CD52 on the cell surface.</li><li>Used for treatment of patients with relapsing forms of MS.</li><li>Emerging use to facilitate engraftment of allogeneic or off-the-shelf CAR T cells.</li></ul><a href=#cyclophosphamide><h3 id=cyclophosphamide><span class=hanchor arialabel=Anchor># </span>Cyclophosphamide</h3></a><ul><li>Alkylating agent targeting T cells.</li><li>Multiple indications for use in pediatrics and adults with malignancies and minimal change nephrotic syndrome.</li><li>Could be used for eradicating T cells.</li><li>Limited experience (single case report) in the use for refractory CRS/ICANS.</li></ul><hr><a href=#tkis><h2 id=tkis><span class=hanchor arialabel=Anchor># </span>TKIs</h2></a><a href=#dasatinib-tki-bcr-abl><h3 id=dasatinib-tki-bcr-abl><span class=hanchor arialabel=Anchor># </span>Dasatinib: TKI (BCR-ABL)</h3></a><ul><li>Used for adults in chronic, accelerated, or blast phase of Ph+ CML; for adults with Ph+ ALL.</li><li>Preclinical studies demonstrate the ability of dasatinib to suppress CAR T-cell cytotoxicity, cytokine secretion, and proliferation.</li></ul><a href=#ibrutinib><h3 id=ibrutinib><span class=hanchor arialabel=Anchor># </span>Ibrutinib</h3></a><ul><li>BTK inhibitor.</li><li>Used for adults with MCL who have received at least 1 prior therapy, for CLL with 17p deletion, or in those who have received at least 1 prior therapy or who have Waldenstrom macroglobulinemia.</li><li>Emerging clinical data incorporating ibrutinib suggest the potential of reducing CRS severity.</li></ul><hr><a href=#ruxolitinib-or-alternative-jak1-inhibitors><h3 id=ruxolitinib-or-alternative-jak1-inhibitors><span class=hanchor arialabel=Anchor># </span>Ruxolitinib or alternative JAK1 inhibitors</h3></a><ul><li><strong>JAK inhibitor</strong>.</li><li>Used for the treatment of adults with myelofibrosis and polycythemia vera, and for the treatment of adults and pediatric patients aged >12 y with steroid refractory acute GVHD or chronic GVHD after failure of >1-2 lines of systemic therapy.</li><li>Preclinical studies demonstrate a role of JAK pathway singling blockade and dose-dependent reduction of multiple cytokines implicated in CRS.</li></ul><hr><a href=#car-t-cell-construct-based-safety-switches-in-cd19-car-t-cell-therapy><h2 id=car-t-cell-construct-based-safety-switches-in-cd19-car-t-cell-therapy><span class=hanchor arialabel=Anchor># </span>CAR T-Cell Construct-Based Safety Switches in CD19 CAR T-cell Therapy</h2></a><p>TODO: Áúã‰∏çÂ§™ÊáÇÈÄôÊòØ‰ªÄÈ∫º</p><ul><li>CAR T-cell constructs can incorporate suicide switches or alternative transcriptional controls</li><li>Suicide switches can be targeted by the synthetic dimerizing drug rimiducid</li><li>Truncated-targetable receptors, such as EGFR or CD20, can be targeted by monoclonal antibodies like cetuximab or rituximab</li><li>These agents can be used to eradicate CAR T cells in cases of refractory disease or life-threatening CAR T-cell‚Äìmediated toxicities.</li></ul><hr><a href=#anti-car-t-cell-directed-strategies><h3 id=anti-car-t-cell-directed-strategies><span class=hanchor arialabel=Anchor># </span>Anti-CAR T-cell-directed strategies</h3></a><ul><li>When patients have severe or refractory CRS and/or ICANS, targeting the remaining CAR T cells is often the last resort.</li><li>Anti-CAR T-cell‚Äìdirected interventions may include chemotherapy, T-cell‚Äìdirected therapies, tyrosine kinase inhibitors, or CAR construct‚Äìdirected therapies.</li><li>Experience with these interventions is limited, and infection risk may be particularly high, especially when given after multiple prior immunosuppressive approaches.</li><li>Further studies are needed to evaluate the efficacy and safety of these interventions for the treatment of severe or refractory CRS/ICANS.</li></ul><hr><a href=#supportive-care-measures-for-management-of-severe-or-refractory-toxicities-in-cd19-car-t-cell-therapy><h2 id=supportive-care-measures-for-management-of-severe-or-refractory-toxicities-in-cd19-car-t-cell-therapy><span class=hanchor arialabel=Anchor># </span>Supportive Care Measures for Management of Severe or Refractory Toxicities in CD19 CAR T-cell Therapy</h2></a><ul><li>management of:<ul><li>cytopenias</li><li>infections</li><li>hypotension</li><li>coagulopathy</li><li>electrolyte disturbances</li></ul></li><li>Early intervention and management of adverse effects may improve patient outcomes and reduce the risk of long-term complications.</li></ul><hr><a href=#supportive-care-measures-for-patients-with-severe-or-refractory-crs-or-icans-in-cd19-car-t-cell-therapy><h2 id=supportive-care-measures-for-patients-with-severe-or-refractory-crs-or-icans-in-cd19-car-t-cell-therapy><span class=hanchor arialabel=Anchor># </span>Supportive Care Measures for Patients with Severe or Refractory CRS or ICANS in CD19 CAR T-cell Therapy</h2></a><a href=#neurology><h3 id=neurology><span class=hanchor arialabel=Anchor># </span>Neurology</h3></a><ul><li>Identify patients at high risk of developing ICANS and engage neurology early.</li><li>Tailor duration of steroids in patients with severe ICANS to treat toxicity but limit adverse side effects.</li></ul><a href=#immunehematologic><h3 id=immunehematologic><span class=hanchor arialabel=Anchor># </span>Immune/Hematologic</h3></a><ul><li>Limit the duration of high-dose steroids for the management of toxicity to diminish immune suppression.</li><li>Use cytokine-directed treatments, such as anakinra, as a steroid-sparing approach.</li><li>Optimize approaches to treat ongoing cytopenias.</li></ul><hr><a href=#infectious-disease><h3 id=infectious-disease><span class=hanchor arialabel=Anchor># </span>Infectious Disease</h3></a><ul><li><strong>trimethoprim-sulfamethoxazole</strong>, for Pneumocystis jirovecii prophylaxis.</li><li>Ppx acyclovir or valacyclovir, for herpes virus prophylaxis before conditioning chemotherapy.</li><li>broad-spectrum antibiotics and blood cultures for patients with neutropenic fever.</li><li>Assess for CMV, adeno- or other viremias in patients with persistent cytopenia after treatment.</li><li>antifungal prophylaxis in patients with prolonged immunosuppression due to CRS/ICANS management and cytopenias.</li></ul><hr><a href=#rehabilitation><h3 id=rehabilitation><span class=hanchor arialabel=Anchor># </span>Rehabilitation</h3></a><ul><li>Involve inpatient rehabilitation services for patients, particularly those with lengthy hospital stays or those who received prolonged steroids, after they are clinically stable.</li><li>Encourage engagement of caregivers and social workers.</li></ul><a href=#cognitivepsychosocial><h3 id=cognitivepsychosocial><span class=hanchor arialabel=Anchor># </span>Cognitive/Psychosocial</h3></a><ul><li>Consult psychiatry or psychiatric oncology to aid in the management of delirium, particularly in older or pediatric patients who develop ICANS.</li></ul><hr><a href=#medical><h3 id=medical><span class=hanchor arialabel=Anchor># </span>Medical</h3></a><ul><li>Patients with severe or refractory CRS and/or ICANS typically receive prolonged courses of high-dose corticosteroids with other immunosuppressive agents.</li><li>To mitigate the deleterious effects of corticosteroids, the use of steroid-sparing, cytokine-directed medications for prophylaxis, or treatment of CAR-mediated toxicity should be assessed.</li><li>Infectious complications are frequent after CAR T-cell therapy, and severe CRS and prolonged corticosteroid exposure are risk factors for severe infections.</li><li>Prophylactic antimicrobials are essential to reduce infections, including emergence of latent and opportunistic infections.</li><li>Exposure to broad-spectrum antibiotics targeting obligate anaerobes within the 4 weeks before CAR T-cell therapy has been associated with worse outcomes, possibly because of alterations in the intestinal microbiome.</li><li>The impact of antibiotics administered after CAR T-cell therapy is not yet known.</li></ul><hr><a href=#rehabilitation-and-cognitive-and-psychosocial-considerations><h3 id=rehabilitation-and-cognitive-and-psychosocial-considerations><span class=hanchor arialabel=Anchor># </span>Rehabilitation and cognitive and psychosocial considerations</h3></a><ul><li>Multiple factors, including CRS and ICANS, immobility, malnutrition, infection, and the catabolic effects of prolonged corticosteroids, may lead to a deterioration in the conditioning and mental status</li><li>Early considerations for rehabilitation to address deconditioning and steroid myopathy that may result in proximal limb weakness is needed</li><li>Emerging research suggests the presence of short- and long-term biobehavioral effects of CAR T-cell therapy, but more work is needed in this area to understand the long-term implications for patients who experience severe or refractory CAR-mediated toxicities.</li></ul><hr><a href=#conclusions><h2 id=conclusions><span class=hanchor arialabel=Anchor># </span>Conclusions</h2></a><p><img src=https://i.imgur.com/cgvReVa.png width=auto alt="Figure: height:550px"></p><hr><a href=#take-home-messages><h2 id=take-home-messages><span class=hanchor arialabel=Anchor># </span>Take Home Messages</h2></a><ul><li>Prophylaxis and early treatment of CRS appear to play a role in preventing subsequent severe toxicity in CD19 CAR T-cell therapy.</li><li>Rates of severe CRS and ICANS may depend on histology, tumor burden, and CAR T-cell product type, making interpretation of single-arm trials challenging.</li><li>Caution is needed because limited data is available on the effect of these interventions on antitumor efficacy, and patients at lower risk typically do not need these interventions.</li></ul><hr><hr><a href=#thank-you-for-your-time-and-attention><h1 id=thank-you-for-your-time-and-attention><span class=hanchor arialabel=Anchor># </span>Thank you for your time and attention</h1></a><a href=#have-a-nice-day><h1 id=have-a-nice-day><span class=hanchor arialabel=Anchor># </span><em>Have a nice day</em></h1></a><p><img src="https://emojik.vercel.app/s/%e2%98%80%ef%b8%8f_%f0%9f%98%8e?size=256" width=auto alt="emojik RLQ height:300px"></p></article><hr><div class=page-end id=footer><div class=backlinks-container><h3>‚Ü©Ô∏è ÂèçÂêëÈÄ£Áµê</h3><ul class=backlinks><li>ü§≠Ê≤íÊúâÊâæÂà∞ÂèçÂêëÈÄ£Áµê</li></ul></div><div><script async src=https://cdn.jsdelivr.net/npm/d3@6.7.0/dist/d3.min.js integrity="sha256-+7jaYCp29O1JusNWHaYtgUn6EhuP0VaFuswhNV06MyI=" crossorigin=anonymous></script><h3>ü§Ø‰∫íÂãïÂúñ</h3><div id=graph-container></div><style>:root{--g-node:var(--secondary);--g-node-active:var(--primary);--g-node-inactive:var(--visited);--g-link:var(--outlinegray);--g-link-active:#5a7282}</style><script src=https://www.physician.tw/js/graph.2d9e48dbe7ea47c0ef1c58296ce14448.js></script></div></div><div><div id=disqus_thread></div><script type=application/javascript>window.disqus_config=function(){},function(){if(["localhost","127.0.0.1"].indexOf(window.location.hostname)!=-1){document.getElementById("disqus_thread").innerHTML="Disqus comments not available by default when the website is previewed locally.";return}var t=document,e=t.createElement("script");e.async=!0,e.src="//physician.disqus.com/embed.js",e.setAttribute("data-timestamp",+new Date),(t.head||t.body).appendChild(e)}()</script><noscript>Please enable JavaScript to view the <a href=https://disqus.com/?ref_noscript>comments powered by Disqus.</a></noscript><a href=https://disqus.com class=dsq-brlink>comments powered by <span class=logo-disqus>Disqus</span></a></div><div id=contact_buttons><footer><p>Êú¨Á∂≤Á´ôÊòØÁî± Hsieh-Ting Lin ‰ª•‚ù§Ô∏è Áî® <a href=https://github.com/jackyzha0/quartz>Quartz</a>ÈÄôÂÄãÈÖ∑Êù±Ë•øÁ®ÆÂá∫‰æÜü™¥ , ¬© 2023</p><p><a href=https://www.buymeacoffee.com/htl.lizard><img src=https://cdn.buymeacoffee.com/buttons/v2/default-yellow.png width=200></a></p><ul><li><a href=https://www.physician.tw/>üè†È¶ñÈ†Å</a></li><li><a href=https://www.facebook.com/htlin.lizard>Facebook</a></li><li><a href=https://twitter.com/htlin222>Twitter</a></li><li><a href=https://github.com/htlin222>GitHub</a></li><li><a href=https://htlin.site>Blog</a></li><li><a href=https://htlin222.medium.com>Medium</a></li></ul></footer></div></div></body></html>